2019
DOI: 10.1159/000495517
|View full text |Cite
|
Sign up to set email alerts
|

Amelioration of Early Markers of Diabetic Nephropathy by Linagliptin in Fructose-Streptozotocin-Induced Type 2 Diabetic Rats

Abstract: Background: Early prediction and clinical intervention are extremely important in order to delay or hinder diabetic nephropathy (DN) progression. Objectives: This study aimed to detect early signs of DN and study the potential ameliorating effect of the dipeptidyl peptidase-4 inhibitor, linagliptin, on some early markers for DN in fructose-streptozotocin (Fr-STZ)-induced diabetic rats. Method: Fr-STZ rats were treated with either linagliptin (3 mg/kg p.o. daily), metformin (350 mg/kg p.o. daily), or their comb… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

2
8
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 13 publications
(14 citation statements)
references
References 68 publications
2
8
0
Order By: Relevance
“…Additionally, DPP4 represents a precise druggable target in CKD. These DPP4 inhibitors were proved to exhibit renoprotective effects and ameliorate the glomerulosclerosis and tubulointerstitial fibrosis in different diseases ( Kanasaki et al, 2014 ; Vavrinec et al, 2014 ; Tanaka et al, 2016 ; Tsuprykov et al, 2016 ; Uchida et al, 2017 ; Oraby et al, 2019 ; Pengrattanachot et al, 2020 ; Tang et al, 2021 ).…”
Section: Ferroptosis Regulators and Renal Fibrosismentioning
confidence: 99%
“…Additionally, DPP4 represents a precise druggable target in CKD. These DPP4 inhibitors were proved to exhibit renoprotective effects and ameliorate the glomerulosclerosis and tubulointerstitial fibrosis in different diseases ( Kanasaki et al, 2014 ; Vavrinec et al, 2014 ; Tanaka et al, 2016 ; Tsuprykov et al, 2016 ; Uchida et al, 2017 ; Oraby et al, 2019 ; Pengrattanachot et al, 2020 ; Tang et al, 2021 ).…”
Section: Ferroptosis Regulators and Renal Fibrosismentioning
confidence: 99%
“…Nakashima et al reported that linagliptin attenuates albuminuria in T1D rats by downregulating the AGE-RAGE axis independent of the glucose-lowering effects [87]. Linagliptin has been shown to inhibit tubular damage by attenuating oxidative stress, inflammation, and fibrosis in fructose-STZ (Fr-STZ)-induced diabetic rats, as proven by reductions in the levels of kidney injury molecule (KIM)-1 and neutrophil gelatinase-associated lipocalin (NGAL) [88]. Linagliptin has also been shown to attenuate albuminuria and kidney hypertrophy in a glucose-reduction-independent manner by upregulating renal antioxidants catalase and manganese superoxide dismutase (MnSOD) levels [89].…”
Section: Diabetic Animal Modelsmentioning
confidence: 99%
“…According to a US Renal Data System report, 20-40% of diabetic patients in the United States display different degrees of renal injury, and DN is the first secondary factor leading to ESRD (3). The main clinical features of DN are proteinuria, progressive renal impairment and hypertension (4,5), and its prognosis and outcome are associated with a variety of mechanisms, such as hemodynamic changes, oxidative stress and inflammation. Therefore, research should be conducted to further understand the pathogenesis of DN, in order to develop novel therapeutic agents.…”
Section: Introductionmentioning
confidence: 99%